I live about 20 miles away from Dow (NYSE: DOW ) headquarters, so understandably I’ve had my eye on that company for a very, very long time. The price has been dropping for a while, fueled in no small part byI’m Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared in Forbes, Toronto Star, Minneapolis Star-Tribune, Providence Journal, Washington Times and the Detroit Free Press, as well as American Conservative Magazine and the Quincy Institute for Responsible Statecr ...

Company AnnouncementNo. 1/2025                    Copenhagen, 10 February 2025 Proposals for motions to be includedin the agenda of the Annual General Meeting As previously announced, the Annual General Meeting of Scandinavian Tobacco Group A/Swill take place on 9 April 2025. Shareholders who wish to have a proposed motion included in the agenda of the AnnualGeneral Meeting must inform the Board of Directors of Scandinavian Tobacco Group A/Sin writing. Requests must be received no later than 25 February 202 ...

Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical industry. At recent prices, you can buy shares of Merck (MRK -0.88%) that offer a yield above 3%, and shares of Pfizer (PFE -0.35%) offer a yield above 6%.Which of these two high-yield dividend payers is best for your portfolio? Let's weigh their strong points against some of the challenges they face, to see which stock is a better buy now.The case for MerckShares of Merck have fallen ...

We reiterated our bullish stance in Star Group, L.P. (NYSE: SGU ) in early September of last year due to the company's bullish technicals, elevated gross margin & volume growth. Although temperatures in recent years are on average well above historic readings, SGUIndividual investor with a keen interest in deriving income from investment setups. We do this by buying undervalued profitable stocks with strong balance sheets & minimal debt. Furthermore, when the opportunity arises, we like to write calls again ...

Despite supplying some of the world's most sought-after chips, Advanced Micro Devices (AMD -2.36%) has declined 49% since it peaked in March 2024. Over the same period, Nvidia stock has increased about 40%.Nvidia makes the most advanced graphics processing units (GPUs) for data centers, which are used to develop artificial intelligence (AI) models. The company has benefited from a powerful first-mover advantage, capturing the lion's share of the market and adding trillions of dollars to its market capitaliz ...

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road. If you're more of a cautious investor, you can aim for a well-established and diversified player that pays dividends and is known for steady earnings growth. Finally, investors looking for recovery stories also may find opportunity here; as pharma companies lose exclusivity on key products, they often reinvest in their pipelines ...

This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility: Nokia chief executive Pekka Lundmark (L) stands next to chairwoman Sari Baldauf (C) and his successor Justin Hotard (R), the head of AI at Intel. Finnish telecommunications equipment giant Nokia announced on Monday that chief executive Pekka Lundmark would step down and be replaced by Justin Hotard, the head of AI and data cente ...

Artificial intelligence (AI) has probably been the hottest investment theme on the planet over the past year. Companies involved in this high-growth area have seen their share prices climb in the triple digits and have fueled gains in the three major benchmarks -- the S&P 500, the Dow Jones Industrial Average, and the Nasdaq.Investors have piled into AI stocks because of the technology's potential to streamline processes and develop game-changing new products and services. Today's $200 billion AI market is ...

Core Insights - WuXi Biologics has been recognized as a 2025 Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics, marking the fifth consecutive year of high ESG Risk Ratings [1][2] - The company ranks in the top 1% of companies assessed in the pharmaceutical industry, highlighting its strong ESG achievements [2] Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics [5] - The company employs over 12,000 skilled employees across multiple countries, including China, the United States, Ireland, Germany, and Singapore [6] ESG Commitment - The company views Environmental, Social, and Governance (ESG) responsibilities as integral to its business strategy and aims to be a leader in the biologics CRDMO sector [7] - WuXi Biologics has made significant progress in its ESG strategy, receiving various accolades such as the MSCI AAA Rating and inclusion in the Dow Jones Sustainability Indices for two consecutive years [3] Achievements and Recognition - The company has been included in the UNGC 20 Case Examples of Sustainable Development and awarded the Platinum Medal by EcoVadis [3] - WuXi Biologics has also been recognized in the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score [3]

Core Viewpoint - The article emphasizes the importance of conducting personal due diligence before making investment decisions, highlighting that the content is not investment advice and reflects the author's opinions [2][3]. Group 1 - The article clarifies that it is not an investment research report and does not provide personalized investment advice [2][3]. - It states that past performance is not indicative of future results, and any projections or estimates are based on assumptions that may not reflect actual events [3]. - The author disclaims any liability for errors or omissions in the information provided, indicating that the data is obtained from sources believed to be reliable but not guaranteed [2][3].